Company Overview and News

5
MGEN / Miragen Therapeutics FORM 8-K (Current Report)

2018-10-01 sec.gov - 4
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

1
MGEN / Miragen Therapeutics null

2018-08-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
MGEN

1
MGEN / Miragen Therapeutics 10-Q (Quarterly Report)

2018-08-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MGEN

1
MGEN / Miragen Therapeutics FORM 8-K (Current Report)

2018-08-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

1
MGEN / Miragen Therapeutics FORM 8-K (Current Report)

2018-08-06 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

1
miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

2018-07-31 globenewswire
BOULDER, Colo., July 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is scheduled to provide a company overview at the 2018 Wedbush PacGrow Healthcare Conference at 10:20 am EDT on Tuesday, August 14, 2018, at the Le Parker Meridien Hotel in New York.
MGEN

1
miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018

2018-07-25 globenewswire
BOULDER, Colo., July 25, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Tuesday, August 7, 2018, at 4:30 p.m. ET to discuss its financial results for the second quarter 2018.
MGEN

35
Your Daily Pharma Scoop: Kamada Phase 3 Approved, Vivus Positive, IsoRay Down

2018-07-12 seekingalpha - 10
CHMP on board with design of late-stage study of Kamada's inhaled AAT for AATD; shares up 4% premarket
VVUS RSLS MNOV SUMM MGEN ISR KMDA SMMT ACHN SCYX

1
MGEN / Miragen Therapeutics 8-K (Current Report)

2018-07-10 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

60
10 Top Stock Ideas to Beat the Blues

2018-07-06 investorplace
The market isn’t looking cheery right now. In between choppy trading conditions and market pullbacks, who knows where to turn for the remaining half of 2018? However, there are still gems to be found. You just have to be more selective, and more active in your research.
WFCNP FB ALB MGEN TWLO WFC NBL AIMT ZAYO HIIQ BABA S

44
MGEN / Miragen Therapeutics 8-K (Current Report)

2018-06-28 sec.gov - 1
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

44
MGEN / Miragen Therapeutics 8-K (Current Report)

2018-06-04 sec.gov - 1
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

43
Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting

2018-06-04 globenewswire
BOULDER, Colo., June 04, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced the first observations on the safety and efficacy of cobomarsen in adult T-cell leukemia/lymphoma (ATLL) patients, a highly morbid T-cell malignancy seen in patients previously infected with the human T-lymphotropic virus type 1 (HTLV1).
MGEN

43
MGEN / Miragen Therapeutics null

2018-05-22 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
MGEN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MGEN / Miragen Therapeutics on message board site Silicon Investor.

Amgen Inc. (AMGN) Amgen Inc. (AMGN) Amgen Inc. (AMGN) Micro General Corp. OTCBB: MGEN Micro General Corp. OTCBB: MGEN Micro General Corp. OTCBB: MGEN
planet 411.com (formerly ComGen CGEE) planet 411.com (formerly ComGen CGEE) planet 411.com (formerly ComGen CGEE) ComGen Corp (CGEE) ComGen Corp (CGEE) ComGen Corp (CGEE)
AMGEN AMGEN AMGEN
CUSIP: 60463E103